Ticker | CHD | Earnings Date | July 31, 2026 |
Reporting Period | Q2 2026 (ending June 30, 2026) | Prepared | July 30, 2026 |
Last Earnings | May 1, 2026 (Q1 2026) | Sector ETF | XLP (Consumer Staples Select Sector SPDR) |
Key Takeaway: The setup is mixed — CHD beat handily in Q1 but guided Q2 adjusted EPS to $0.88, well below the then-consensus of ~$0.93, making the bar achievable; the single biggest swing factor is whether transportation/commodity cost mitigation is tracking ahead of schedule, which could allow a modest EPS beat even against a reset bar.
Heading into the Q2 2026 print, the bar has been deliberately reset lower: management guided Q2 adjusted EPS to $0.88 on the May 1 call, a figure that sat materially below the pre-print Street consensus and has since been largely adopted by analysts, leaving consensus at ~$0.89. Organic sales growth of ~3% is the guided target for the quarter, with gross margin expansion of only ~50 bps — a step-down from Q1's stronger delivery — as Middle East-driven transportation and commodity cost pressures are expected to peak in Q2 before productivity offsets kick in during H2. Management's tone at the June 2 Deutsche Bank conference was explicitly optimistic, reiterating all full-year targets (3–4% organic growth, 5–8% EPS growth, $1.15B cash flow) with CFO McChesney noting "far more tailwinds" than headwinds from the May 1 vantage point, suggesting no deterioration in the underlying business. Estimate revisions have been stable-to-slightly-down since the Q1 print — the Q2 EPS consensus moved from ~$0.93 pre-print to ~$0.89 post-print and has barely budged since, implying the Street has fully digested the guidance reset without further cuts, which is a mild positive. The stock has traded essentially flat since the Q1 print (up ~2% vs. XLP up ~1.5%), suggesting the market has neither priced in a beat nor a miss, leaving the stock setup neutral. The key wildcard is Touchland consumption trajectory — management maintained double-digit full-year growth expectations despite a tracked-channel slowdown in Q1, and any Q2 data point (positive or negative) on Touchland's untracked-channel performance could move sentiment disproportionately given the brand's premium valuation contribution.
Key Takeaway: Consensus reflects management's own Q2 guidance almost exactly, making the bar achievable but not low; organic sales growth (~3%) is the bigger swing factor given Q1's 5% beat, while EPS ($0.88–$0.89) is tightly anchored to guidance and leaves little room for surprise in either direction.
KPI | Last Quarter Actual (Q1 2026) | Prior Year Period (Q2 2025 Actual) | Q2 2026 Consensus Estimate | YoY Change | Q2 2026 Guidance (Mgmt) | Consensus vs. Guidance |
Net Sales ($M) | $1,469.3M | $1,506.3M | $1,502.9M | -0.2% YoY | ~-1% reported (organic ~+3%) | ~+0.2% above guidance midpoint |
Organic Sales Growth (%) | +5.0% | +0.1% | ~+3.3% | +3.2 pp YoY | ~+3% | ~+30 bps above guidance |
Adj. EPS - Diluted - Operating ($) | $0.95 | $0.94 | $0.89 | -5.3% YoY | $0.88 | +$0.01 / +1.1% above guidance |
Gross Profit - Operating ($M) | $681.4M | $677.4M | $683.7M | +0.9% YoY | ~+50 bps expansion | Broadly in line with guidance |
Sources: Visible Alpha Consensus and Actuals Data (Net Sales, Organic Growth, Adj. EPS, Gross Profit). Q2 2026 guidance from CHD Q1 2026 Earnings Call (May 1, 2026) and Deutsche Bank Global Consumer Conference (June 2, 2026).
Quarter | Reported | Consensus | Surprise (pp) | Result |
Q2 2024 | +4.3% | +3.3% | +1.0 pp | Beat |
Q3 2024 | +4.3% | +3.3% | +1.0 pp | Beat |
Q4 2024 | +4.2% | +3.0% | +1.2 pp | Beat |
Q1 2025 | -1.2% | +1.5% | -2.7 pp | Miss |
Q2 2025 | +0.1% | -0.7% | +0.8 pp | Beat |
Q3 2025 | +3.4% | +1.5% | +1.9 pp | Beat |
Q4 2025 | +0.7% | +1.7% | -1.0 pp | Miss |
Q1 2026 | +5.0% | +3.4% | +1.6 pp | Beat |
Quarter | Reported | Consensus | Surprise (%) | Result |
Q2 2024 | $0.94 | $0.85 | +10.6% | Beat |
Q3 2024 | $0.79 | $0.68 | +16.2% | Beat |
Q4 2024 | $0.77 | $0.77 | 0.0% | In Line |
Q1 2025 | $0.91 | $0.90 | +1.1% | Beat |
Q2 2025 | $0.94 | $0.85 | +10.6% | Beat |
Q3 2025 | $0.81 | $0.74 | +9.5% | Beat |
Q4 2025 | $0.86 | $0.83 | +3.6% | Beat |
Q1 2026 | $0.95 | $0.93 | +2.2% | Beat |
Pattern: CHD has beaten adjusted EPS consensus in 7 of the last 8 quarters, with the sole exception being Q4 2024 (in-line). Organic sales beats are also the norm (6 of 8), with the two misses concentrated in Q1 2025 (VMS divestiture drag) and Q4 2025 (portfolio transition). The consistent EPS beat pattern reflects CHD's tendency to guide conservatively, though the Q2 2026 guidance was unusually specific ($0.88) and well-telegraphed, which may limit upside surprise.
Source: Visible Alpha Consensus and Actuals Data.
Key Takeaway: Full-year 2026 guidance has been fully reiterated since the May 1 Q1 print with no changes; tone has shifted modestly more optimistic at the June 2 Deutsche Bank conference, with CFO McChesney citing "far more tailwinds" and expressing confidence in the H2 productivity ramp.
Metric | Initial Guidance (May 1, 2026 Q1 Call) | Revised Guidance | Current Consensus | Note |
FY2026 Organic Sales Growth | ~3% to 4% | — | ~3.8% | Reiterated at DB Conference June 2; unchanged |
FY2026 Reported Sales Growth | -1.5% to -0.5% | — | ~-0.5% | Unchanged; reflects VMS/portfolio exit drag |
FY2026 Adj. EPS Growth | +5% to +8% | — | ~+6.5% (implies ~$3.75) | Reiterated at DB Conference June 2; unchanged |
FY2026 Gross Margin Expansion | ~+100 bps vs. 2025 | — | In line with guidance | Unchanged; productivity offsets Middle East inflation |
FY2026 Marketing (% of Sales) | ~11% | — | ~11% | Unchanged; in line with evergreen model |
FY2026 Free Cash Flow | ~$1.15B | — | ~$1.15B | Reiterated at DB Conference June 2; unchanged |
FY2026 CapEx (% of Sales) | ~2% of sales | — | ~2% of sales | Unchanged |
Q2 2026 Adj. EPS | $0.88 | — | ~$0.89 | Consensus has converged to guidance; no post-call revision |
Q2 2026 Organic Sales Growth | ~+3% | — | ~+3.3% | Consensus slightly above guidance midpoint |
Q2 2026 Gross Margin Expansion | ~+50 bps | — | In line with guidance | Transportation cost pressure peaks in Q2; mitigation in H2 |
Sources: CHD Q1 2026 Earnings Call transcript (May 1, 2026); CHD Deutsche Bank Global Consumer Conference transcript (June 2, 2026); Visible Alpha Consensus Data.
Key Takeaway: Q2 EPS estimates dropped sharply post-Q1 print (from ~$0.93 to ~$0.89) as the Street absorbed the below-consensus Q2 guidance, but have been stable since; full-year estimates have barely moved, suggesting analysts believe the H2 productivity ramp is credible and the full-year guidance range is intact.
KPI (Period) | Estimate ~5 Days Post Q1 Print (as of ~May 8, 2026) | Current Consensus (July 30, 2026) | Estimate Δ (%) | Initial Guidance (May 1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Adj. EPS (Q2 2026) | $0.894 | $0.894 | 0.0% | $0.88 | $0.88 (unchanged) | — | +1.6% above guidance |
Organic Sales Growth (Q2 2026) | ~+3.2% | ~+3.3% | +0.1 pp | ~+3% | ~+3% (unchanged) | — | +30 bps above guidance |
Net Sales (Q2 2026) | $1,497.4M | $1,502.9M | +0.4% | ~-1% reported | ~-1% reported (unchanged) | — | Broadly in line |
Adj. EPS (FY2026) | $3.749 | $3.753 | +0.1% | +5% to +8% growth | +5% to +8% (unchanged) | — | ~+6.5% growth; mid-range of guidance |
Organic Sales Growth (FY2026) | ~+3.8% | ~+3.8% | 0.0% | ~3% to 4% | ~3% to 4% (unchanged) | — | Near top of guidance range |
Net Sales (FY2026) | $6,147.1M | $6,177.9M | +0.5% | -1.5% to -0.5% reported | -1.5% to -0.5% (unchanged) | — | Near top of guidance range |
The key takeaway from the revision tracker is that the Street has fully absorbed the Q2 guidance reset and has not made further cuts — a sign of confidence in the H2 productivity ramp. Full-year estimates are essentially unchanged since the Q1 print, implying analysts believe the $25–30M Middle East cost headwind is manageable and that the back-half acceleration in gross margin is credible.
Source: Visible Alpha Consensus and Actuals Data (as-of date: May 8, 2026 for baseline; current as of July 30, 2026). Guidance from CHD Q1 2026 Earnings Call (May 1, 2026).
Key Takeaway: CHD has essentially tracked XLP since the Q1 print, with modest multiple expansion (+1–2%) driving the slight outperformance rather than estimate revisions (which were flat); the stock has not priced in a beat or a miss, leaving the setup balanced.
Since the Q1 2026 earnings date (May 1, 2026), CHD closed at $96.02 on that day and traded to $97.68 by July 31, 2026 — a gain of approximately +1.7% on an absolute basis. Over the same period, XLP (Consumer Staples Select Sector SPDR ETF) gained approximately +1.5% and the S&P 500 (SPY) gained approximately +2.9%. CHD thus slightly outperformed XLP but lagged the broader market. The stock's NTM P/E has expanded modestly from ~25.2x to ~25.5x over the past three months, consistent with the broader consumer staples re-rating. The performance decomposition confirms that multiple expansion, not estimate revisions, drove the modest outperformance — a pattern that is typical for CHD in periods of stable guidance. No material single-day moves occurred post-Q1 print, with the stock's intraday range on May 1 (from ~$96 to a pre-market high before settling) being the largest event. The stock's relative flatness vs. XLP suggests the market is treating CHD as a sector-neutral hold heading into Q2 results.
Date | CHD (Indexed) | XLP (Indexed) | SPY (Indexed) |
May 1, 2026 (Base = 100) | 100.0 | 100.0 | 100.0 |
May 8, 2026 | 97.3 | 100.0 | 102.4 |
May 22, 2026 | 100.2 | 100.7 | 103.5 |
June 2, 2026 (DB Conference) | 100.1 | 97.2 | 105.4 |
June 16, 2026 | 102.5 | 101.7 | 104.1 |
June 30, 2026 | 100.9 | 98.7 | 103.6 |
July 16, 2026 | 103.2 | 101.9 | 104.2 |
July 29, 2026 | 104.0 | 103.8 | 101.2 |
July 31, 2026 (Latest) | 101.7 | 101.5 | 102.9 |
Note: Indexed to 100 at May 1, 2026 close. CHD = $96.02, XLP = $84.17, SPY = $720.65. Key event marked: June 2, 2026 — Deutsche Bank Global Consumer Conference (guidance reiterated, optimistic tone). Sector ETF: XLP (Consumer Staples Select Sector SPDR) — appropriate for CHD's household and personal care sub-sector.
Source: Stock Price Data (Yahoo Finance).
Key Takeaway: The most important post-Q1 development is the Miss Mouth's Messy Eater acquisition close (late May 2026), which adds a fast-growing digitally-native stain fighter brand with low household penetration and significant distribution runway; the deal is EPS-neutral in 2026 and accretive to cash earnings in 2027, so it is not a near-term EPS swing factor but validates CHD's M&A pipeline and brand-building strategy.
Key Takeaway: All five insider transactions since the Q1 print are open-market sales — no open-market buys — but the sales are clustered in June and appear to be discretionary (no 10b5-1 plan flags in the data); the volume is modest relative to holdings and does not constitute a strong negative signal, though the absence of any buying is worth noting.
Name | Title | Transaction Type | Shares | Date | Note |
Linares, Carlos G. | EVP, Chief Technology & Global New Products | Open Market Sale | 10,000 | June 16, 2026 | Discretionary; no 10b5-1 plan. Leaves 4,668 shares post-sale. |
Shearer, Robert K. | Director | Open Market Sale | 8,600 | June 11, 2026 | Discretionary; no 10b5-1 plan. Retains 39,278 shares. |
Buchert, Brian D. | EVP of Strategy, M&A, and Business Planning | Open Market Sale | 10,160 | June 10, 2026 | Discretionary; no 10b5-1 plan. Leaves only 1,286 shares post-sale — notable reduction. |
Saligram, Ravichandra K. | Director | Open Market Sale (Indirect) | 12,960 | June 10, 2026 | Held via revocable trust; no 10b5-1 plan. Retains 13,653 shares. |
Price, Penry W. | Director | Open Market Sale | 5,960 | May 13, 2026 | Discretionary; no 10b5-1 plan. Retains 30,070 shares. |
The cluster of five sales across two directors and three executives in May–June 2026 is notable in its breadth, though the individual amounts are modest relative to retained holdings for most sellers. The most notable transaction is Buchert (EVP Strategy & M&A) reducing his direct holding to just 1,286 shares — a near-full liquidation of his direct position. No open-market buys were recorded in the period. No 10b5-1 plan flags were present in the data, suggesting these are discretionary sales, though the timing (post-Q1 beat, stock near $95–$98) is consistent with opportunistic profit-taking rather than a negative fundamental signal.
Source: SEC Form 4 Filings (Insider Transaction Data).
Key Takeaway: Peer commentary from May–June 2026 consistently points to a stressed but resilient consumer, flat-to-low-single-digit category growth, and meaningful Middle East-driven commodity/transportation cost pressure — all consistent with CHD's own Q2 guidance. The read-throughs are directionally supportive of CHD's organic growth target (~3%) but reinforce that gross margin expansion will be limited in Q2, with recovery dependent on H2 productivity execution.
Note on scope: Only commentary from the last 60 days (on or after May 30, 2026) that explicitly addresses calendar Q2 2026 / June-quarter conditions or forward outlook is included below. Retrospective Q1 2026 results commentary from peers is excluded. Each read-through includes explicit limitations.
Relevance: CLX is CHD's closest household cleaning peer, with overlapping categories (laundry, cleaning, litter). CLX's CFO provided explicit Q2 2026 (CLX's fiscal Q4) cost and margin commentary.
CHD Read-Through: CLX's ~150 bps gross margin headwind from Middle East costs in calendar Q2 is directionally consistent with CHD's own guidance of only ~50 bps gross margin expansion in Q2 (vs. ~100 bps for the full year), implying the cost pressure is real and front-loaded. The "flat to 1%" category growth observation is more bearish than CHD's own Q2 organic growth guidance of ~3%, but CHD's portfolio skews more toward personal care and premium brands with higher category growth rates. The value-seeking consumer dynamic benefits CHD's ARM & HAMMER franchise.
Limitations: CLX's fiscal Q4 ends in June, so the timing aligns with CHD's Q2, but CLX's category mix (heavy in cleaning/disinfecting) differs from CHD's more diversified personal care/household portfolio. CLX's specific gross margin figures are not directly comparable to CHD's cost structure or hedging position.
Relevance: PG is the largest household and personal care peer, with broad category overlap. PG's fiscal Q4 (ending June 2026) commentary is directly relevant to CHD's Q2 2026 conditions.
CHD Read-Through: PG's confirmation that "almost all" of its $150M Middle East cost headwind hits in calendar Q2 2026 is a strong read-through for CHD's own Q2 gross margin pressure. The surfactant supply disruption (20% of global feedstock lost) is directly relevant to CHD's cleaning and laundry products. PG's international strength (4% category growth) is a positive read-through for CHD's International segment, which management guided to ~7% organic growth for the full year. The U.S. consumer stability at 2–3% over rolling 12-week periods is broadly consistent with CHD's ~3% Q2 organic growth guidance.
Limitations: PG's scale ($80B+ revenue) means its commodity cost figures are not directly translatable to CHD's ~$6B revenue base. PG's Baby Care competitive dynamics (heavy price competition) may not apply to CHD's baby care exposure (WaterWipes). PG's fiscal year ends June 30, so its Q4 commentary is directly calendar-aligned with CHD's Q2.
Relevance: KMB is a household and personal care peer with overlapping consumer demographics and distribution channels. KMB's commentary on Q2 2026 conditions and cost dynamics is relevant to CHD's household segment.
CHD Read-Through: KMB's observation that shipments may lag consumption by ~200 bps in Q2 is a useful caution for interpreting CHD's reported net sales vs. organic growth. The resilient North American consumer for daily-use staples is broadly supportive of CHD's household and personal care volumes. KMB's strong international performance (Brazil, Indonesia, Vietnam) is a positive read-through for CHD's International segment. KMB's disciplined promotional posture suggests the competitive environment in household/personal care is not aggressively promotional, which is favorable for CHD's margins.
Limitations: KMB's categories (diapers, bath tissue, feminine care) are less price-elastic than some of CHD's personal care categories. KMB's specific productivity program metrics are not directly comparable to CHD's cost structure. The international markets cited (Brazil, Indonesia, Vietnam) may not overlap with CHD's primary international markets.
Relevance: ELF is a digitally-native personal care/beauty brand with overlapping consumer demographics to CHD's premium personal care brands (TheraBreath, Touchland, Hero). ELF's commentary on consumer sentiment and price elasticity in Q2 2026 is relevant to CHD's premium brand portfolio.
CHD Read-Through: ELF's observation of "higher unit decline" and high price elasticity in the personal care/beauty space is a mild negative read-through for CHD's premium personal care brands (TheraBreath, Touchland, Hero), which are also in the early household penetration phase and dependent on consumer willingness to try premium products. The "challenging consumer segment" commentary reinforces CHD's own cautious tone on the consumer. However, CHD's value brands (ARM & HAMMER) are insulated from this dynamic and may benefit from trade-down. The U.K. promotional environment is worth monitoring for CHD's international segment.
Limitations: ELF operates primarily in cosmetics/skincare, which has different demand elasticity and consumer drivers than CHD's household cleaning and oral care categories. ELF's tariff refund is a unique situation with no direct CHD analog. The price elasticity data points are specific to ELF's price points and product categories.
Relevance: CL is a direct peer in oral care (overlapping with CHD's TheraBreath and ARM & HAMMER oral care) and household products. CL's commentary on North American demand deceleration in early Q2 2026 is the most timely and specific read-through available.
CHD Read-Through: CL's observation of North American category deceleration in early May 2026 is the most directly relevant and timely read-through for CHD's Q2 organic growth. If the "markedly slow" trend in the first weeks of May persisted through June, CHD's ~3% Q2 organic growth guidance could be at risk — though CHD's portfolio mix (more personal care, less oral care) and its ARM & HAMMER value positioning may provide some insulation. CL's Latin America resilience is a positive read-through for CHD's International segment. CL's shift from gross margin expansion to contraction guidance is a cautionary signal for CHD's own ~50 bps Q2 gross margin expansion target.
Limitations: CL's North America deceleration observation was based on only 3 weeks of data from early May and management explicitly noted it was "too early to tell" if the trend would persist. CL's oral care category dynamics may not fully translate to CHD's oral care brands (TheraBreath is a premium therapeutic brand with different demand drivers than commodity toothpaste). CL's gross margin guidance shift reflects its own cost structure and hedging position, which differs from CHD's.
Peer | Event Date | Key Q2 2026 Signal | Direction for CHD | Confidence |
CLX | June 3, 2026 | U.S. categories flat to +1%; Middle East costs = ~150 bps GM headwind in Q2 | Neutral/Negative on GM; Neutral on organic growth (CHD's categories grow faster) | High (direct calendar overlap) |
PG | June 3, 2026 | U.S. consumer stable at 2–3%; intl. categories +4%; Middle East costs peak in fiscal Q4 (= cal. Q2) | Positive on organic growth; Negative on GM (cost peak in Q2) | High (fiscal Q4 = cal. Q2) |
KMB | June 4, 2026 | Consumer resilient for daily-use staples; shipments may lag consumption ~200 bps; intl. very strong | Positive on volumes; caution on reported sales vs. organic gap | Medium (category mix differs) |
ELF | June 4, 2026 | Challenging consumer segment; higher unit decline; high price elasticity; U.K. more promotional | Mild negative for CHD's premium personal care brands (Touchland, Hero, TheraBreath) | Low-Medium (beauty vs. household) |
CL | June 3, 2026 | N. America categories "markedly slow" in early May; LatAm healthy; GM guidance shifted to down | Negative on N. America organic growth risk; Negative on GM; Positive on intl. | Medium (3 weeks of data only; oral care overlap) |
Sources: CLX Deutsche Bank Global Consumer Conference transcript (June 3, 2026); PG Deutsche Bank Global Consumer Conference transcript (June 3, 2026); KMB Deutsche Bank Global Consumer Conference transcript (June 4, 2026); ELF Deutsche Bank Global Consumer Conference transcript (June 4, 2026); CL Deutsche Bank Global Consumer Conference transcript (June 3, 2026).